Non-invasive first trimester blood test reliably detects Down's syndrome

February 02, 2015

Cell-free fetal DNA testing, which measures the relative amount of free fetal DNA in a pregnant woman's blood, is a new screening test that indicates the risk of Down syndrome (trisomy 21), Edward syndrome (trisomy 18), and Patau syndrome (trisomy 13). A recent analysis of 37 published studies shows that the test can detect more than 99% of Down syndrome cases in singleton pregnancies, with a very low false positive rate of less than 0.1%. This makes it superior to all other testing methods.

The test is much less accurate for Edward syndrome and Patau syndrome, however, with respective detection rates of about 96% and 92% and a false positive rate of 0.26%. The analysis is published in Ultrasound in Obstetrics & Gynecology.
-end-


Wiley

Related Trisomy Articles from Brightsurf:

Plant compound reduces cognitive deficits in mouse model of Down syndrome
The plant compound apigenin improved the cognitive and memory deficits usually seen in a mouse model of Down syndrome, according to a study by researchers at the National Institutes of Health and other institutions.

Low risk of COVID-19 infection found among people with congenital heart disease
Results of a retrospective analysis suggest that people born with a heart defect who developed COVID-19 symptoms had a low risk of moderate or severe COVID-19 infection, according to a new article published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.

New insights into why people with down syndrome are at higher risk for leukemia
Scientists from Stanley Manne Children's Research Institute at Ann & Robert H.

Research story tip: Down syndrome mice open door to better understanding of the disorder
Johns Hopkins Medicine researchers and their collaborators have created and characterized a new mouse replica of Down syndrome, long considered one of the most challenging disorders to simulate in laboratory animals.

Genes related to down syndrome abnormalities may protect against solid tumors
Scientists from Stanley Manne Children's Research Institute at Ann & Robert H.

New therapeutic targets for treating memory impairment in Down syndrome
Researchers from Hospital del Mar Medical Research Institute studied the neural basis of intellectual disability in mice with Down syndrome and discovered that the neural networks of brain circuits relevant to memory and learning are over-activated and that the connectivity of these circuits is poor.

Major discovery in the genetics of Down syndrome
New research highlights the RCAN1 gene's effect on memory and learning.

Research supports expanding insurance coverage of non-invasive prenatal testing
Research conducted by the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences provides evidence to support expansion of insurance plan coverage of noninvasive prenatal testing (NIPT), a simple maternal blood draw which screens for fetal chromosomal disorders including trisomy 13 (Patau syndrome), trisomy 18 (Edwards syndrome), and trisomy 21 (Down syndrome), to women under the age of 35.

Exploring the risk of ALL in children with Down syndrome
Researchers discovered new clues that provide a better understanding of why children with Down syndrome have an increased risk of leukemia.

Advanced data analysis enhances precision medicine application in clinics
Scientists have published a novel computational framework for highly accurate and targeted Non-Invasive Prenatal genetic Testing (NIPT) assay, which enables the application of cost-effective TAC-seq laboratory method in clinical practice.

Read More: Trisomy News and Trisomy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.